These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37821080)

  • 21. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
    Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence.
    van Besien K; Dew A; Lin S; Joseph L; Godley LA; Larson RA; Odenike T; Rich E; Stock W; Wickrema A; Artz AS
    Leuk Lymphoma; 2009 Nov; 50(11):1809-17. PubMed ID: 19821799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with a Reduced Toxicity Allogeneic Transplant Regimen for Non-CGD Primary Immune Deficiencies Requiring Myeloablation.
    Chandra S; Chandrakasan S; Dávila Saldaña BJ; Bleesing JJ; Jordan MB; Kumar AR; Grimley MS; Krupski C; Davies SM; Khandelwal P; Marsh RA
    J Clin Immunol; 2021 Jan; 41(1):89-98. PubMed ID: 33067658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders.
    Madden LM; Hayashi RJ; Chan KW; Pulsipher MA; Douglas D; Hale GA; Chaudhury S; Haut P; Kasow KA; Gilman AL; Murray LM; Shenoy S
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1467-1472. PubMed ID: 27164064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fludarabine-based reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in primary hemophagocytic lymphohistiocytosis.
    Hamidieh AA; Pourpak Z; Hashemi S; Yari K; Fazlollahi MR; Movahedi M; Behfar M; Moin M; Ghavamzadeh A
    Eur J Haematol; 2014 Apr; 92(4):331-6. PubMed ID: 24330187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for mixed chimerism in children with hemophagocytic lymphohistiocytosis after reduced toxicity conditioning.
    Wustrau K; Greil J; Sykora KW; Albert MH; Burkhardt B; Lang P; Meisel R; Wössmann W; Beier R; Schulz A; Bader P; Chada M; Kühl JS; Schlegel PG; Speckmann C; Gruhn B; Seidel M; Wawer A; Ozga AK; Janka G; Ehl S; Müller I; Lehmberg K
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28523. PubMed ID: 32618429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and Outcomes of Central Nervous System Hemophagocytic Lymphohistiocytosis Relapse after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
    Lounder DT; Khandelwal P; Chandra S; Jordan MB; Kumar AR; Grimley MS; Davies SM; Bleesing JJ; Marsh RA
    Biol Blood Marrow Transplant; 2017 May; 23(5):857-860. PubMed ID: 28219834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alemtuzumab and CXCL9 levels predict likelihood of sustained engraftment after reduced-intensity conditioning HCT.
    Geerlinks AV; Scull B; Krupski C; Fleischmann R; Pulsipher MA; Eapen M; Connelly JA; Bollard CM; Pai SY; Duncan CN; Kean LS; Baker KS; Burroughs LM; Andolina JR; Shenoy S; Roehrs P; Hanna R; Talano JA; Schultz KR; Stenger EO; Lin H; Zoref-Lorenz A; McClain KL; Jordan MB; Man TK; Allen CE; Marsh RA
    Blood Adv; 2023 Jul; 7(14):3725-3734. PubMed ID: 37042921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total Marrow Irradiation for Second Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia.
    Dominietto A; Vagge S; di Grazia C; Bregante S; Raiola AM; Varaldo R; Gualandi F; Gusinu M; Barra S; Agostinelli S; Angelucci E; Hui S
    Transplant Cell Ther; 2023 Aug; 29(8):506.e1-506.e6. PubMed ID: 37094701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.
    Holtan SG; Hogan WJ; Elliott MA; Ansell SM; Inwards DJ; Porrata LF; Johnston PB; Micallef IN; Lacy MQ; Gastineau DA; Litzow MR
    Bone Marrow Transplant; 2010 Dec; 45(12):1699-703. PubMed ID: 20208572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
    Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
    Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
    Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis.
    Murthy GSG; Kim S; Estrada-Merly N; Abid MB; Aljurf M; Assal A; Badar T; Badawy SM; Ballen K; Beitinjaneh A; Cerny J; Chhabra S; DeFilipp Z; Dholaria B; Perez MAD; Farhan S; Freytes CO; Gale RP; Ganguly S; Gupta V; Grunwald MR; Hamad N; Hildebrandt GC; Inamoto Y; Jain T; Jamy O; Juckett M; Kalaycio M; Krem MM; Lazarus HM; Litzow M; Munker R; Murthy HS; Nathan S; Nishihori T; Ortí G; Patel SS; Van der Poel M; Rizzieri DA; Savani BN; Seo S; Solh M; Verdonck LF; Wirk B; Yared JA; Nakamura R; Oran B; Scott B; Saber W
    Haematologica; 2023 Jul; 108(7):1900-1908. PubMed ID: 36779595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
    Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treosulfan-based conditioning regimen for children and adolescents with hemophagocytic lymphohistiocytosis.
    Lehmberg K; Albert MH; Beier R; Beutel K; Gruhn B; Kröger N; Meisel R; Schulz A; Stachel D; Woessmann W; Janka G; Müller I
    Haematologica; 2014 Jan; 99(1):180-4. PubMed ID: 24162790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low Incidence of Relapse with a Moderate Conditioning Regimen of Fludarabine, Busulfan, and Melphalan for Patients with Myeloid Malignancies: A Single-Center Analysis of 100 Patients.
    Jiang JL; Gao WH; Wang LN; Wan M; Wang L; Hu J
    Transplant Cell Ther; 2023 Aug; 29(8):512.e1-512.e8. PubMed ID: 37263418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD3
    Ramanathan S; Lum SH; Nademi Z; Carruthers K; Watson H; Flood T; Owens S; Williams E; Hambleton S; Gennery AR; Slatter M
    Transplant Cell Ther; 2023 Aug; 29(8):513.e1-513.e9. PubMed ID: 37279857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases.
    Parikh SH; Mendizabal A; Benjamin CL; Komanduri KV; Antony J; Petrovic A; Hale G; Driscoll TA; Martin PL; Page KM; Flickinger K; Moffet J; Niedzwiecki D; Kurtzberg J; Szabolcs P
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):326-36. PubMed ID: 24296492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.